Surgery Plus Chemo Versus Chemoradiotherapy Followed by Surgery Plus Chemo for Locally Recurrent Rectal Cancer
Status:
Recruiting
Trial end date:
2028-10-01
Target enrollment:
Participant gender:
Summary
JCOG1801 is a randomized phase III trial which was initiated in Japan in August 2019 to
confirm the superiority of preoperative chemoradiotherapy followed by surgery plus adjuvant
chemotherapy for local relapse-free survival over standard treatment, i.e. surgery plus
adjuvant chemotherapy, for previously non-irradiated locally recurrent rectal cancer.
Phase:
Phase 3
Details
Lead Sponsor:
National Cancer Center Hospital East
Collaborators:
Japan Agency for Medical Research and Development Japan Clinical Oncology Group